Model Informed Drug Development Archives

Blog

拥抱模型引导的药物发现：通往更佳临床疗效之路

We cover the evidence of biosimulation improving clinical success rates, making the case for model-informed…

Certara2026 年 2 月 27 日

博客

Rare Disease Day 2026: Accelerating Rare Disease Drug Development Through Cross-Functional Innovation

On Rare Disease Day 2026, Certara experts share how cross-functional innovation, regulatory strategies for rare…

Certara2026 年 2 月 26 日

Live Events

Certara Biotech Forum: Workshop on Developing Investor-Ready Strategies

–

Certara2026 年 2 月 24 日

Webinar

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Danielle Pillsbury2026 年 2 月 23 日

Blog

FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development

Learn what the ICH M15 guideline means for Model-Informed Drug Development, regulatory credibility, harmonization, and…

Certara2026 年 2 月 18 日

Guide

Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD)

Prepare for ICH M15 guideline: Learn how to assess model credibility, align terminology, and strengthen…

Certara2026 年 2 月 13 日

Live Events

Certara IQ^™ Global Roadshow

Certara IQ™ is going on the road. From APAC to Europe to North America, our…

Certara2026 年 2 月 12 日

Live Events

Certara IQ™ Workshop

Certara2026 年 2 月 11 日

Blog

Pediatric Drug Development: From “Wild West” to Model-Informed Confidence

Model-informed drug development and precision dosing are transforming pediatric programs, from regulatory planning to Bayesian…

Certara2026 年 2 月 11 日

Publication

Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants

This study, published in Clinical Pharmacology & Therapeutics (CPT), shows how population pharmacokinetic modeling supports…

Certara2026 年 2 月 2 日

模型引导的药物开发

拥抱模型引导的药物发现：通往更佳临床疗效之路

Rare Disease Day 2026: Accelerating Rare Disease Drug Development Through Cross-Functional Innovation

Certara Biotech Forum: Workshop on Developing Investor-Ready Strategies

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development

Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD)

Certara IQ^™ Global Roadshow

Certara IQ™ Workshop

Pediatric Drug Development: From “Wild West” to Model-Informed Confidence

Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants

订阅时事通讯

快捷链接

解决方案

联系我们